Akademik Veri Yönetim Sistemi
Journal of Neurological Sciences, cilt.32, sa.4, ss.767-772, 2015 (SCI-Expanded, Scopus, TRDizin)
Introduction: Essential thrombocytosis (ET) is a myeloproliferative disease ongoing with megakaryocytic hyperplasia in bone marrow and with an increased risk of both bleeding and thrombosis. Macro- and microvascular events can be seen in ET. Macrovascular events are frequently arterial, and less commonly venous. Case: A 30-year-old woman presented with unhealed pain on the right side of the head for the preceding 2 months. No abnormal finding was determined at neurological examination apart from bilateral papillary edema. Biochemistry tests were normal except count of platelet. MR venography revealed thrombosis in the superior sagittal sinus and transverse sinus. Presence of JAK2 V617F mutation and presence of BCR/ABL were analysed owing to elevated platelet counts, and JAK2 V617F mutation resulted positive. She was started acetazolamide 250 mg for the headache and the patient was started hydroxyurea 1x500 mg. No decrease in platelet counts was observed with hydroxyurea, and the dose was raised to 1500 mg, at which platelet counts changed back into normal. Discussion and Conclusion: Essential thrombocytosis; can often be diagnosed before serious complications develop since it is easily detected at routine tests. Macrovascular events include coronary artery disease, cerebrovascular event, deep vein thrombosis. CVT is not commonly encountered among the complications seen in ET. The patient was started the cytoreductive agent hydroxyurea and in maintenance treatment. While CVT is not common in ET, JAK2 mutation must be investigated in the presence of CVT among young women patients and in the presence of thrombocytosis.